All In Biotech

Free tool

FAERS Monitor: Ferabright

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219868 or its brand name (Ferabright, Ferumoxytol). Reports on generic versions are filed under their own applications.

Reports

239

Serious

178

74% of reports

Hospitalization

59

Death reported

20

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea66
  • infusion related reaction65
  • nausea33
  • anaphylactic reaction28
  • back pain22
  • vomiting22
  • dizziness20
  • chest discomfort19
  • flushing19
  • hypotension17
  • chest pain13
  • hypertension13
  • cardio-respiratory arrest11
  • abdominal pain10
  • headache10

Reports by year received

View as table
YearReports
20103
20115
20125
20137
20144
201510
20165
20174
201812
201915
202013
202124
202222
202316
202425
202537
202632

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,920 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal6586.470.25,412
anaphylactic reactionSignal2844.631.51,153
cardio-respiratory arrestSignal1123.213.0212
flushingSignal1916.510.7262
chest discomfortSignal1916.310.6260
dyspnoeaSignal6610.38.4557
back painSignal228.35.6136
hypotensionSignal177.54.790
chest painSignal136.23.652
hypertensionSignal135.43.243
vomitingSignal224.12.850
abdominal painSignal103.82.118
nauseaSignal333.72.764
dizzinessSignal203.52.335
headache101.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.